The discovery of underlying mechanisms of drug resistance and the development of novel agents to target these pathways is a priority for patients with advanced colorectal cancer (CRC). The aim of this study was to identify novel targets whose knock-down is important in mediating sensitivity to 5-FU and oxaliplatin in Kras wild type and mutant CRC models. Materials and Methods. Transcriptional profiling (Almac Diagnostics Colorectal Cancer Disease Specific Array'") of pre-treatment metastatic CRC liver biopsies and oxaliplatin/5-FU resistant HCTl16 cell lines followed by Pathway Analysis and Gene Set Enrichment Analysis (GSEA) were used to identify individual genes from novel drug-sensitivity pathways for incorporation into a RNAi screen. Re...
Le cancer colorectal est un cancer majeur en termes de fréquence et de mortalité. Il s’agit de la de...
Recently, evidence has accumulated that weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with...
Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens...
The stromal cell-derived factor-1 (SDF-1)/CXC receptor 4 (CXCR4) axis plays an important role in tum...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have b...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have b...
FOLFOXIRI, i.e., the combination of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan, is a ...
The general goal of this thesis is to create a better insight into the genes and signaling proteins ...
[[abstract]]BACKGROUND: Colorectal cancer (CRC), the most common cancer type, causes high morbidity ...
[[abstract]]Oxaliplatin (OXA), is a third generation platinum drug used as first-line chemotherapy i...
AbstractA systemic approach was used to identify the possible mechanisms underlying the development ...
The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the t...
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuo...
Abstract Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer...
Colorectal cancer (CRC) is a widespread tumour type amongst men and women. Despite the available scr...
Le cancer colorectal est un cancer majeur en termes de fréquence et de mortalité. Il s’agit de la de...
Recently, evidence has accumulated that weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with...
Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens...
The stromal cell-derived factor-1 (SDF-1)/CXC receptor 4 (CXCR4) axis plays an important role in tum...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have b...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have b...
FOLFOXIRI, i.e., the combination of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan, is a ...
The general goal of this thesis is to create a better insight into the genes and signaling proteins ...
[[abstract]]BACKGROUND: Colorectal cancer (CRC), the most common cancer type, causes high morbidity ...
[[abstract]]Oxaliplatin (OXA), is a third generation platinum drug used as first-line chemotherapy i...
AbstractA systemic approach was used to identify the possible mechanisms underlying the development ...
The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the t...
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuo...
Abstract Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer...
Colorectal cancer (CRC) is a widespread tumour type amongst men and women. Despite the available scr...
Le cancer colorectal est un cancer majeur en termes de fréquence et de mortalité. Il s’agit de la de...
Recently, evidence has accumulated that weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with...
Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens...